These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 8604318

  • 1. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.
    Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA.
    Nucleic Acids Res; 1996 Feb 15; 24(4):737-45. PubMed ID: 8604318
    [Abstract] [Full Text] [Related]

  • 2. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix.
    Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA.
    J Biol Chem; 1995 Feb 10; 270(6):2620-7. PubMed ID: 7852327
    [Abstract] [Full Text] [Related]

  • 3. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent.
    Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zeltser R, Stec W, Stein CA.
    Nucleic Acids Res; 1995 Nov 11; 23(21):4239-45. PubMed ID: 7501441
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CpG ODN-mediated regulation of IL-12 p40 transcription.
    Takeshita F, Klinman DM.
    Eur J Immunol; 2000 Jul 11; 30(7):1967-76. PubMed ID: 10940886
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis.
    Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R.
    Anticancer Res; 1996 Jul 11; 16(1):61-9. PubMed ID: 8615671
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antisense therapy of cancer.
    Narayanan R.
    In Vivo; 1994 Jul 11; 8(5):787-93. PubMed ID: 7727726
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide.
    Benimetskaya L, Berton M, Kolbanovsky A, Benimetsky S, Stein CA.
    Nucleic Acids Res; 1997 Jul 01; 25(13):2648-56. PubMed ID: 9185577
    [Abstract] [Full Text] [Related]

  • 17. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo.
    Kitajima I, Unoki K, Maruyama I.
    Antisense Nucleic Acid Drug Dev; 1999 Apr 01; 9(2):233-9. PubMed ID: 10355829
    [Abstract] [Full Text] [Related]

  • 18. Controversies in the cellular pharmacology of oligodeoxynucleotides.
    Stein CA.
    Ciba Found Symp; 1997 Apr 01; 209():79-89; discussion 89-93. PubMed ID: 9383570
    [Abstract] [Full Text] [Related]

  • 19. Amplification of antibody production by phosphorothioate oligodeoxynucleotides.
    Branda RF, Moore AL, Lafayette AR, Mathews L, Hong R, Zon G, Brown T, McCormack JJ.
    J Lab Clin Med; 1996 Sep 01; 128(3):329-38. PubMed ID: 8783641
    [Abstract] [Full Text] [Related]

  • 20. Concerning antisense inhibition of the multiple drug resistance gene.
    Jaroszewski JW, Kaplan O, Syi JL, Sehested M, Faustino PJ, Cohen JS.
    Cancer Commun; 1990 Sep 01; 2(8):287-94. PubMed ID: 2202383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.